Would you consider modifying the dose for focal prostate boost to other fractionation schedules?

DELINEATE was a phase II trial from the NHS which was designed to evaluate the toxicity of a simultaneous integrated boost (SIB) to the mpMRI-defined dominant intraprostatic nodule (DIL) for two fractionation schedules: conventional fractionation (cohort A) and hypofractionation in 20 fractions (coh...

I have done some patients with 70 in 28 fractions with 2.7 to 2.8 Gy SIB dose with same isotoxic OAR dose principle.

Yes. I do not think we need separate RCTs for each fractionation schedule. The principles from FLAME readily apply: you can do a focal tumor boost up to the point where you will meaningfully impact toxicity risk.

I have used up to 74 Gy in 20 fractions and up to 84 Gy in 28 fractions. Using a/b=1.2 f...